Tags : AVEO Oncology


Insights+: The US FDA New Drug Approvals in March 2021

The US FDA has approved 7 NDAs in Mar 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 19 novel products in 2021. Additionally, last year in 2020, the US FDA has approved […]Read More


AstraZeneca and AVEO Oncology Enter into an Immuno-Oncology Clinical Collaboration

Shots: AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019, with equal cost sharing Imfinzi (durvalumab) is mAb binds with PD-L1, further blocking its interaction with PD-1 and […]Read More